Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zika virus vaccine (recombinant protein) + Advax
- Development stage
- Preclinical
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a preclinical-stage recombinant protein vaccine candidate developed by Vaxine for the prevention of Zika virus infection. The vaccine consists of a recombinant Zika virus envelope (E) protein formulated with Vaxine's proprietary Advax adjuvant, which is based on delta-inulin. The mechanism of action involves the induction of high-titer neutralizing antibodies and protective immunity against the Zika virus by targeting the viral envelope protein, which is essential for viral attachment and entry into host cells. Advax adjuvant is designed to enhance the immune response without the typical inflammatory side effects associated with traditional adjuvants.
- Other names
- Zika envelope protein + Advax vaccine
02
Targets
ZIKV EDIII (Zika virus envelope protein domain III)EDIII (Dengue virus and West Nile virus envelope protein domain III)
Beyond the preview
Go deeper on zika virus vaccine (recombinant protein) + Advax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zika virus vaccine (recombinant protein) + Advax.